

APR 08 2005

KLARQUIST SPARKMAN, LLP

INTELLECTUAL PROPERTY LEGAL SERVICES • INCLUDING PATENTS, TRADEMARKS, COPYRIGHTS & LITIGATION • SINCE 1941
One World Trade Center • 121 S.W. Salmon Street • Suite 1600 • Portland, Oregon 97204 • U.S.A.
Telephone: 503-595-5300 • www.klarquist.com
Facsimile: 503-595-5301

FAX TRANSMITTAL

DATE: April 8, 2005

TO: Qian Janice Li

FAX PHONE NO.: 703-872-9306

FROM: Deborah Martin, Assistant to
Sheree Lynn Rybak, Ph.D.

RE: U.S. Application No. 09/857,719 filed 12/3/2001
For GENE THERAPY FOR CARDIOMYOPATHY

OUR FILE: 6235-59216-01

NO. OF PAGES 3 (including this cover page)

PLEASE ACKNOWLEDGE RECEIPT BY RETURN FACSIMILE? ☐ Yes ☒ No

CONFIRMATION TO FOLLOW? ☐ Yes ☒ No

CONTACT INFO: If you do not receive all pages or if you have problems receiving transmittal, please call us at (503) 595-5300 as soon as possible and ask for Deborah Martin.

MESSAGE: Examiner Li--Attached are pages 1 and 11 of the specification, as you requested by telephone on April 7, 2005.

THE INFORMATION CONTAINED IN THIS TRANSMISSION IS CONFIDENTIAL AND ONLY FOR THE INTENDED RECIPIENT IDENTIFIED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION OR USE OF THIS COMMUNICATION IS UNLAWFUL. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE (COLLECT), RETURN THE ORIGINAL MESSAGE TO US, AND RETAIN NO COPY.

DESCRIPTION

GENE THERAPY FOR CARDIOMYOPATHY

5 Technical Field

The present invention relates to a method of gene therapy for treating myocardial pathology by noninvasive administration of an HGF (hepatocyte growth factor) gene and therapeutic agents used therefor. More specifically, the present invention relates to a method of gene therapy for treating myocardial pathology by noninvasive administration of an HGF gene into the cardiac muscle, especially to a method of gene therapy that more efficiently treats heart disease, such as cardiomyopathy, angina pectoris and heart failure, by injecting an HGF gene into the affected part of cardiac muscle under the usage of echo, and to therapeutic agents used therefor. Moreover, the present invention relates to a method of gene therapy which is applicable to genes other than HGF genes and that consists of administering genes to the affected part of tissue noninvasively under the usage of echo.

20 Background Art

In spite of the recent striking technical improvements in the medical field, many problems remain unsolved. The problem of myocardial pathology is one of the important unsolved subjects.

Myocardial pathology is a general name for diseases attributable to organic and functional abnormalities of the cardiac muscle. For example, cardiomyopathy is classified into secondary cardiomyopathy, which occurs in sequence to hypertension, dysrhythmia, ischemic disease and such, and idiopathic cardiomyopathy (ICM), which occurs without any distinct fundamental disease. Hypertrophic cardiomyopathy (HCM) is classified as an ICM, whose cause of disease is most revealed at the genetic level. In half the numbers of patients with HCM, familial history following autosomal dominant heredity is recognized. Linkage analysis of such family lines, with multiple patients as the object, revealed 5 causal loci so far and the causal gene itself is specified in 4 of them.

Many cases of dilated cardiomyopathy (DCM) occur independently,

(LamatLB9507 (BERTHOLO)).

2. Under the usage of echocardiogram (MD500, YOKOKAWA-GE), HVJ-liposome agent was injected into the abdominal lateral cardiac muscle of the heart of myocardiopathy hamster (12 weeks old) and was subjected to following investigations:

1) Density of blood capillary in the cardiac muscle was measured by ALP (alkaline phosphatase) staining and the result of the HGF gene was compared to that of the control.

2) Bloodstream of the heart to which HVJ-liposome was administered was evaluated by laser Doppler imager (LDI) score and the result of the HGF gene was compared to that of the control.

3) After Masson staining of the cardiac muscle, distribution density of fibrosis was measured by computer analysis. Result of the HGF gene was compared to that of the control.

Reference 1

Preparation of HVJ-liposome agent

10 mg Dried lipid (a 1:4.8:2 mixture of phosphatidyl serine, phosphatidyl choline and cholesterol) and 200 μ l balanced salt solution (137 μ M NaCl, 5.4 μ M KCl, 10 μ M Tris-HCl; pH7.6) containing HGF gene (100 μ g)-HMG1 (high mobility group 1 nuclear protein, 25 μ g) was mixed and, by stirring vigorously with ultrasonication, liposomes were formed. Purified Sendai virus (Z strain) was irradiated with UV (110erg/ mm^2/sec) for 3 minutes. Liposome suspension was mixed with Sendai virus (HVJ), heated at 4°C for 10 minutes, and then heated at 37°C for 30 minutes. Free HVJ was discarded and thus obtained HVJ liposome agent.

Reference 2

Measurement on luciferase activity

Liposome agent with 10 μ g of luciferase gene was administered to hamsters (6 animals per group). A week later, luciferase activity was measured. Results are shown in Figure 1.

As shown in Figure 1, high levels of luciferase activity were exhibited in the heart. Thus, it was revealed that gene transfer under the usage of echo is possible.